Cargando…
Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema
Up to now alpha 1-antitrypsin (AAT) augmentation therapy has been approved only for commercial use in selected adults with severe AAT deficiency-related pulmonary emphysema (i.e. PI*ZZ genotypes as well as combinations of Z, rare and null alleles expressing AAT serum concentrations <11 μmol/L). H...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094201/ https://www.ncbi.nlm.nih.gov/pubmed/21486454 http://dx.doi.org/10.1186/1750-1172-6-14 |